Page last updated: 2024-09-05

tesaglitazar and drf 2725

tesaglitazar has been researched along with drf 2725 in 6 studies

Compound Research Comparison

Studies
(tesaglitazar)
Trials
(tesaglitazar)
Recent Studies (post-2010)
(tesaglitazar)
Studies
(drf 2725)
Trials
(drf 2725)
Recent Studies (post-2010) (drf 2725)
7413254134

Protein Interaction Comparison

ProteinTaxonomytesaglitazar (IC50)drf 2725 (IC50)
Chain A, peroxisome proliferator activated receptor gammaHomo sapiens (human)0.092
Peroxisome proliferator-activated receptor gammaHomo sapiens (human)0.092
Peroxisome proliferator-activated receptor alphaHomo sapiens (human)0.98

Research

Studies (6)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's3 (50.00)29.6817
2010's3 (50.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Deussen, HJ; Ebdrup, S; Fleckner, J; Frost Jensen, A; Mortensen, SB; Nygaard, L; Pettersson, I; Pridal, L; Rasmussen, HB; Sauerberg, P1
Henke, BR1
Kagechika, K; Kubo, H; Shibata, Y; Usui, H; Yamaguchi, M1
Hashimoto, Y; Ishikawa, M; Makishima, M; Noguchi-Yachide, T; Okazaki, S; Shioi, R; Yamaguchi, T1
Kaya, T; Sheu, SH; Vajda, S; Waxman, DJ1
Farkouh, M; Plutzky, J; Rosenson, RS; Wright, RS1

Reviews

2 review(s) available for tesaglitazar and drf 2725

ArticleYear
Peroxisome proliferator-activated receptor alpha/gamma dual agonists for the treatment of type 2 diabetes.
    Journal of medicinal chemistry, 2004, Aug-12, Volume: 47, Issue:17

    Topics: Animals; Diabetes Mellitus, Type 2; Humans; Hyperglycemia; Hypoglycemic Agents; Models, Molecular; Molecular Structure; Receptors, Cytoplasmic and Nuclear; Transcription Factors

2004
Modulating peroxisome proliferator-activated receptors for therapeutic benefit? Biology, clinical experience, and future prospects.
    American heart journal, 2012, Volume: 164, Issue:5

    Topics: Alkanesulfonates; Diabetic Angiopathies; Glycine; Humans; Hypoglycemic Agents; Insulin Resistance; Ligands; Oxazines; Oxazoles; Phenylpropionates; Phosphorylation; PPAR alpha; PPAR delta; PPAR gamma; Thiazolidinediones; Thiophenes; United States; United States Food and Drug Administration

2012

Other Studies

4 other study(ies) available for tesaglitazar and drf 2725

ArticleYear
Synthesis and biological and structural characterization of the dual-acting peroxisome proliferator-activated receptor alpha/gamma agonist ragaglitazar.
    Journal of medicinal chemistry, 2003, Apr-10, Volume: 46, Issue:8

    Topics: Binding Sites; Crystallography, X-Ray; Hypoglycemic Agents; Ligands; Models, Molecular; Oxazines; Phenylpropionates; Radioligand Assay; Receptors, Cytoplasmic and Nuclear; Stereoisomerism; Transcription Factors

2003
Design, synthesis and evaluation of novel zwitterionic compounds as PPARα/γ dual agonists (1).
    Bioorganic & medicinal chemistry letters, 2012, Dec-01, Volume: 22, Issue:23

    Topics: Animals; Blood Glucose; Drug Design; Mice; PPAR alpha; PPAR gamma; Structure-Activity Relationship; Thiazolidinediones; Triglycerides; Weight Gain

2012
Switching subtype-selectivity: Fragment replacement strategy affords novel class of peroxisome proliferator-activated receptor α/δ (PPARα/δ) dual agonists.
    Bioorganic & medicinal chemistry letters, 2017, 07-15, Volume: 27, Issue:14

    Topics: Acetamides; Binding Sites; Genes, Reporter; HEK293 Cells; Humans; Ligands; PPAR alpha; PPAR delta; Protein Binding; Stereoisomerism; Thiazolidinediones

2017
Exploring the binding site structure of the PPAR gamma ligand-binding domain by computational solvent mapping.
    Biochemistry, 2005, Feb-01, Volume: 44, Issue:4

    Topics: Alkanesulfonates; Binding Sites; Cinnamates; Computational Biology; Humans; Ligands; Oxazines; Oxazoles; Phenylpropionates; PPAR gamma; Protein Binding; Protein Conformation; Protein Interaction Mapping; Protein Structure, Tertiary; Rosiglitazone; Solvents; Thiazoles; Thiazolidinediones; Thiazolidines; Tyrosine

2005